Institution
University of California, San Diego
Education•San Diego, California, United States•
About: University of California, San Diego is a education organization based out in San Diego, California, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 83317 authors who have published 204524 publications receiving 12315489 citations. The organization is also known as: UCSD & UC San Diego.
Topics: Population, Poison control, Gene, Medicine, Cancer
Papers published on a yearly basis
Papers
More filters
•
01 Mar 2013TL;DR: Findings indicate that, in contrast to derivatives of ESCs, abnormal gene expression in some cells differentiated from iPSCs can induce T-cell-dependent immune response in syngeneic recipients.
Abstract: iPSC clones, two reprogrammed with three factors (V3-1 and V3-3) and two with four factors (V4-1 and V4-2), were selected for further analysis (Supplementary Fig. 2h). Most implanted B6 ViPSCs failed to form detectable teratomas or formed teratomas that were subsequently immune-rejected with T cell infiltration and massive necrosis (Supplementary Fig. 3a–e). The teratomas that did not undergo apparent regression were also infiltrated with CD4 1 T cells with apparent
1,187 citations
••
TL;DR: It is shown that cathelicidins are an important native component of innate host defence in mice and provide protection against necrotic skin infection caused by Group A Streptococcus (GAS).
Abstract: In mammals, several gene families encode peptides with antibacterial activity, such as the beta-defensins and cathelicidins. These peptides are expressed on epithelial surfaces and in neutrophils, and have been proposed to provide a first line of defence against infection by acting as 'natural antibiotics'. The protective effect of antimicrobial peptides is brought into question by observations that several of these peptides are easily inactivated and have diverse cellular effects that are distinct from antimicrobial activity demonstrated in vitro. To investigate the function of a specific antimicrobial peptide in a mouse model of cutaneous infection, we applied a combined mammalian and bacterial genetic approach to the cathelicidin antimicrobial gene family. The mature human (LL-37) and mouse (CRAMP) peptides are encoded by similar genes (CAMP and Cnlp, respectively), and have similar alpha-helical structures, spectra of antimicrobial activity and tissue distribution. Here we show that cathelicidins are an important native component of innate host defence in mice and provide protection against necrotic skin infection caused by Group A Streptococcus (GAS).
1,187 citations
••
Charles R. Drew University of Medicine and Science1, RAND Corporation2, University of California, Los Angeles3, Agency for Healthcare Research and Quality4, Kent State University5, University of Pennsylvania6, National Institutes of Health7, University of California, San Diego8, Michigan State University9
TL;DR: Clinicians may need to actively identify those at risk of psychiatric and/or drug dependence disorders and work with policymakers to ensure the availability of appropriate care for these treatable disorders.
Abstract: Background: There have been no previous nationally representative estimates of the prevalence of mental disorders and drug use among adults receiving care for human immunodeficiency virus (HIV) disease in the United States. It is also not known which clinical and sociodemographic factors are associated with these disorders. Subjects and Methods: We enrolled a nationally representative probability sample of 2864 adults receiving care for HIV in the United States in 1996. Participants were administered a brief structured psychiatric instrument that screened for psychiatric disorders (major depression, dysthymia, generalized anxiety disorders, and panic attacks) and drug use during the previous 12 months. Sociodemographic and clinical factors associated with screening positive for any psychiatric disorder and drug dependence were examined in multivariate logistic regression analyses. Results: Nearly half of the sample screened positive for a psychiatric disorder, nearly 40% reported using an illicit drug other than marijuana, and more than 12% screened positive for drug dependence during the previous 12 months. Factors independently associated with screening positive for a psychiatric disorder included number of HIV-related symptoms, illicit drug use, drug dependence, heavy alcohol use, and being unemployed or disabled. Factors independently associated with screening positive for drug dependence included having many HIV-related symptoms, being younger, being heterosexual, having frequent heavy alcohol use, and screening positive for a psychiatric disorder. Conclusions: Many people infected with HIV may also have psychiatric and/or drug dependence disorders. Clinicians may need to actively identify those at risk and work with policymakers to ensure the availability of appropriate care for these treatable disorders.
1,185 citations
••
University of Texas MD Anderson Cancer Center1, University of Rochester2, Medical University of Łódź3, Tom Baker Cancer Centre4, Vita-Salute San Raffaele University5, Tel Aviv University6, Leeds Teaching Hospitals NHS Trust7, Washington University in St. Louis8, North Shore Hospital9, University of Silesia in Katowice10, University of Cambridge11, Royal Bournemouth Hospital12, Stanford University13, University of Melbourne14, University of Eastern Piedmont15, National Academy of Sciences16, Katholieke Universiteit Leuven17, Ghent University18, Masaryk University19, National University of Ireland, Galway20, Gdańsk Medical University21, University of Oxford22, City of Hope National Medical Center23, Hebrew University of Jerusalem24, St. Vincent's Health System25, University of California, San Diego26
TL;DR: Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables.
Abstract: BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. METHODS We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil. The primary end point was progression-free survival as assessed by an independent review committee. RESULTS The median age of the patients was 73 years. During a median follow-up period of 18.4 months, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (hazard ratio, 0.16; P<0.001). Ibrutinib significantly prolonged overall survival; the estimated survival rate at 24 months was 98% with ibrutinib versus 85% with chlorambucil, with a relative risk of death that was 84% lower in the ibrutinib group than in the chlorambucil group (hazard ratio, 0.16; P = 0.001). The overall response rate was higher with ibrutinib than with chlorambucil (86% vs. 35%, P<0.001). The rates of sustained increases from baseline values in the hemoglobin and platelet levels were higher with ibrutinib. Adverse events of any grade that occurred in at least 20% of the patients receiving ibrutinib included diarrhea, fatigue, cough, and nausea; adverse events occurring in at least 20% of those receiving chlorambucil included nausea, fatigue, neutropenia, anemia, and vomiting. In the ibrutinib group, four patients had a grade 3 hemorrhage and one had a grade 4 hemorrhage. A total of 87% of the patients in the ibrutinib group are continuing to take ibrutinib. CONCLUSIONS Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables. (Funded by Pharmacyclics and others; RESONATE-2 ClinicalTrials.gov number, NCT01722487.)
1,184 citations
••
TL;DR: The risk of liver‐related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another.
1,182 citations
Authors
Showing all 84160 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Zhong Lin Wang | 245 | 2529 | 259003 |
Michael Karin | 236 | 704 | 226485 |
Eugene Braunwald | 230 | 1711 | 264576 |
Fred H. Gage | 216 | 967 | 185732 |
Robert J. Lefkowitz | 214 | 860 | 147995 |
Peter Libby | 211 | 932 | 182724 |
Peer Bork | 206 | 697 | 245427 |
Rob Knight | 201 | 1061 | 253207 |
Ronald M. Evans | 199 | 708 | 166722 |
Carlo M. Croce | 198 | 1135 | 189007 |
Lewis C. Cantley | 196 | 748 | 169037 |
John C. Reed | 190 | 891 | 164382 |
Gad Getz | 189 | 520 | 247560 |
Scott M. Grundy | 187 | 841 | 231821 |